NCT05934110进行中（未招募）2 期
A 26-week, Double-blind, Randomized Study in Participants With Overweight or Obesity Investigating the Added Contribution of Acarbose in EMP16 on Efficacy, Safety and Tolerability
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 320
- 试验地点
- 3
- 主要终点
- Proportion of participants with ≥5% decrease in body weight at week 26 [Please note: This is an FDA required outcome, cannot use "change"]
研究概览
简要总结
This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination product with modified release (MR) orlistat, orlistat in its conventional dosage form and placebo.
详细描述
The study will be conducted at 3 research sites in Sweden. A total of 320 randomized patients are expected to participate in the study for approximately 31 weeks, including a screening period of up to 5 weeks and a 26-weeks treatment period.
EMP16 is indicated for people with obesity with an initial BMI ≥ 30 kg/m² or ≥ 27 kg/m² in the presence of other risk factors (e.g., hypertension, glucose dysregulation and T2DM, and/or dyslipidemia).
Participants will be randomized to either of 5 arms:
- EMP16-120/40, 80 participants
- MR orlistat 120 mg, 80 participants
- Conventional orlistat 120 mg, 80 participants
- EMP16-60/20, 40 participants
- Placebo, 40 participants
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
This is a double-blind study, and the allocation of treatments will not be disclosed until clean file has been declared and the database has been locked.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to give written informed consent for participation in the study.
- •Males or females (sex distribution 50:50, preferably ±5%) aged ≥18 years.
- •BMI ≥ 30 or ≥ 27 kg/m² in the presence of other risk factors based on participant interview e.g., hypertension (either or not treated with antihypertensive agents), glucose dysregulation (defined as elevated fasting glucose ≥6.1 mmol/L or HbA1c >42mmol/mol), Type 2 Ddabetes that is treated with lifestyle changes (no medication allowed), and/or dyslipidemia (either or not treated with antihyperlipidemic agents). If indicated, plasma/serum total cholesterol, LDL, HDL, and/or TGs can be measured to verify eligibility as judged by the Investigator.
- •No clinically significant abnormalities regarding physical examination, vital signs, ECG, and laboratory values at the time of the screening visit, as judged by the Investigator.
- •Adequate renal function: creatinine <1.5 times upper limit of normal (ULN).
- •Adequate hepatic function: aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase <2.5 times upper level of normal (ULN) and bilirubin <1.5 times ULN.
排除标准
- •Weight unstable (≥ 5% reported change during the previous 3 months) preceding screening and randomization.
- •Subjects who are pregnant, who are currently breastfeeding, who intend to become pregnant within the period of the study, or who gave birth within the 6 months preceding the screening visit.
- •Type 2 diabetes treated with medication.
- •History or presence of any clinically significant disease, disorder, or history of surgery which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study including but not limited to:
- •GI problems/diseases, e.g., diseases that affect intestinal absorption and peristalsis such as inflammatory bowel diseases, irritable bowel syndrome (IBS) and Hirschsprung's disease
- •Cholestasis
- •Chronical malabsorption syndrome
- •Severe allergic, cardiac, or hepatic disease
- •Previous GI surgery that might influence GI function significantly, such as previous bariatric surgery, and previous gallbladder surgery as judged by the investigator.
- •Potential participants with well-treated chronic diseases (e.g., celiac disease and lactose intolerance) may be included in the study at the discretion of the Investigator.
- •Significant clinical illness within the preceding 2 weeks of the first administration of IMP at the discretion of the Investigator.
- •Any significant medical/surgical procedure or trauma within 4 weeks of the first administration of IMP at the discretion of the Investigator.
- •Any planned major surgery within the duration of the study.
- •Any use of drugs altering glucose metabolism and drugs used for diabetes (A10A and A10B) or drugs that are affected by, or that affect, orlistat and acarbose, within 2 weeks prior to the first administration of IMP.
- •Regular use of prescribed or non-prescribed medication within 2 weeks prior to the first administration of IMP as judged by the Investigator. Patients who are on stable treatment with anti-depressants (e.g., selective serotonin re-uptake inhibitors, SSRI) for at least 2 months can be included at the discretion of the Investigator.
- •Untreated high blood pressure (systolic blood pressure >160 mmHg and diastolic blood pressure >100 mmHg at the screening visit).
- •Known hypersensitivity to any of the test substances.
- •Malignancy within the past 5 years with the exception of in situ removal of basal cell carcinoma.
- •Excessive intake of alcohol, as judged by the Investigator.
- •Current or history of alcohol abuse and/or use of anabolic steroids or drugs of abuse.
- •Positive screen for drugs of abuse, or positive screen for alcohol, at the screening visit (Visit 1).
- •Any positive result at the screening visit (Visit 1) for serum hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency Virus (HIV).
- •Plasma donation within 1 month of the screening visit (Visit 1) or any blood donation (or corresponding blood loss) during the 3 months prior to the screening visit.
- •Administration of another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 3 months of the first administration of IMP in this study. Participants consented and screened but not dosed in previous studies are not excluded.
- •Investigator considers the potential participant unlikely to comply with study procedures, restrictions, and requirements.
研究组 & 干预措施
MR orlistat
Active Comparator
MR orlistat 120 mg, 80 participants.
干预措施: MR orlistat 120 mg (Drug)
EMP16-120/40
Experimental
EMP16 120 mg orlistat/40 mg acarbose (referred to as EMP16-120/40), 80 participants.
干预措施: EMP16-120/40 (Drug)
Conventional orlistat
Active Comparator
Conventional orlistat 120 mg, 80 participants.
干预措施: Conventional orlistat 120 mg, (Drug)
Conventional orlistat
Active Comparator
Conventional orlistat 120 mg, 80 participants.
干预措施: Placebo (Drug)
EMP16-60/20
Experimental
EMP16 60 mg orlistat/20 mg acarbose (referred to as EMP16-60/20), 40 participants.
干预措施: EMP16-60/20 (Drug)
EMP16-60/20
Experimental
EMP16 60 mg orlistat/20 mg acarbose (referred to as EMP16-60/20), 40 participants.
干预措施: Placebo (Drug)
Placebo
Placebo Comparator
Placebo, 40 participants
干预措施: Placebo (Drug)
结局指标
主要结局
Proportion of participants with ≥5% decrease in body weight at week 26 [Please note: This is an FDA required outcome, cannot use "change"]
时间窗: Baseline and week 26
Efficacy endpoints
Relative (%) change from baseline in body weight at week 26
时间窗: Baseline and week 26
Efficacy endpoints
次要结局
- Proportion of participants with ≥5% (secondary and exploratory comparisons) and ≥10% (all comparisons) decrease in body weight at week 18 and week 26(Baseline, week 18 and 26)
- Absolute change from baseline in percentage body fat(Baseline and week 26)
- Absolute change from baseline in waist circumference(Baseline and week 26)
- Absolute change from baseline in Quality of life as measured by the questionnaire EQ-5D-5L (measured as one summative value)(Baseline and week 26)
- Absolute change from baseline in body weight during the 26-weeks treatment period(Baseline to week 26)
- Absolute change from baseline in self reported physical activity, where higher points are given for longer duration of moderate and intense physical activity(Baseline and week 26)
- Absolute change from baseline in fasting total cholesterol(Baseline and week 26)
- Absolute change from baseline in fasting high sensitivity C-reacting protein (hs-CRP)(Baseline and week 26)
- Absolute change from baseline in homeostatic model assessment (HOMA) index(Baseline and week 26)
- Absolute change from baseline in Fatty liver index (FLI)(Baseline and week 26)
- Absolute change from baseline in body weight at week 26(Baseline and week 26)
- Absolute change from baseline in sagittal diameter(Baseline and week 26)
- Absolute change from baseline in fasting glucose(Baseline and week 26)
- Absolute change from baseline in fasting low-density lipoprotein (LDL)(Baseline and week 26)
- Absolute change from baseline in fasting Apolipoprotein A1 (ApoA1)(Baseline and week 26)
- Absolute change from baseline in fasting high-density lipoprotein (HDL)(Baseline and week 26)
- Absolute change from baseline in heart rate(Baseline and week 26)
- Absolute change from baseline in fasting liver enzymes(Baseline and week 26)
- Relative (%) change from baseline in body weight at week 26 (secondary and exploratory comparisons)(Baseline and week 26)
- Relative (%) change from baseline in body weight during the 26-weeks treatment period(Baseline to week 26)
- Absolute change from baseline in body mass index (BMI) measured as weight (kg) divided by height (m) squared(Baseline and week 26)
- Absolute change from baseline in Quality of life as measured by the questionnaire Rand-36 (9 different domains)(Baseline and week 26)
- Absolute change from baseline in fasting Apolipoprotein B (ApoB)(Baseline and week 26)
- Absolute change from baseline in fasting albumin(Baseline and week 26)
- Number of withdrawals from study (total and gastrointestinal [GI] related)(Visit 1 until the end-of-study visit. Assessed at all nine visits (both outpatient and telephone visits))
- Absolute change from baseline in self reported meal pattern. Short questionnaire where points are depending on adherence to the Nordic Nutrition recommendations(Baseline and week 26)
- Absolute change from baseline in self reported sleep, where higher points are given for good sleep duration and good sleep quality(Baseline and week 26)
- Absolute change from baseline in fasting insulin(Baseline and week 26)
- Absolute change from baseline in Visceral adiposity index (VAI)(Baseline and week 26)
- Tolerability, assessed by conventional adverse event (AE) reporting (with special focus on oily spotting and fecal incontinence)(IMP administration until the end-of-study visit. Assessed at all nine visits (both outpatient and telephone visits))
- Absolute change from baseline in fasting hemoglobin A1c (HbA1c)(Baseline and week 26)
- Absolute change from baseline in fasting triglycerides (TGs)(Baseline and week 26)
- Absolute change from baseline in systolic and diastolic blood pressure(Baseline and week 26)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityOverweightObesityNCT06200467Boehringer Ingelheim110
已完成
2 期
Evaluating the Safety and Efficacy of Euiiyin-tang on ObesityObesityNCT01724099Kyunghee University Medical Center149
终止
4 期
Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 YearsObesityNCT03338296Eisai Inc.278
已完成
2 期
A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT03745937MedImmune LLC20
已完成
1 期
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityObesityNCT04561245Altimmune, Inc.100